NASDAQ · RLMD
Relmada Therapeutics, Inc.
$3.36-$0.09 (-2.47%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.06% below the high.
Loading market information…
NASDAQ · MNOV · USD
Stock price, earnings
Quote as of Oct 30, 2026, 02:16 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MediciNova, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
MediciNova, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow MediciNova, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| May 14, 2025 |
| -$0.06+57.14% vs estimate |
| $0.00 |
| Q4 2024 | Feb 19, 2025 | -$0.060.0% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 14, 2024 | -$0.060.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $6.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.36-$0.09 (-2.47%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.06% below the high.
$0.42-$0.00 (-0.26%)
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.58% below the high.
$7.49-$0.31 (-3.95%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.05% below the high.
$1.33-$0.02 (-1.48%)
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.27% below the high.
$1.69-$0.07 (-3.98%)
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 52.53% below the high.
$1.27-$0.09 (-6.3%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.77% below the high.
$1.94-$0.06 (-3.0%)
Fortress Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.17% below the high.
$1.95+$0.01 (+0.49%)
XBiotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.33% below the high.
